secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0000950170-22-015232
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences: BEACON Phase 3 tarcocimab meets primary endpoint in retinal vein occlusion
--------------------------------------------------------------------------------

- BEACON Phase 3 randomized 568 RVO patients to tarcocimab 5 mg q8w after 2 monthly loads vs aflibercept 2 mg q4w.
- Primary endpoint of non-inferior BCVA change at week 24 met in BRVO (p=0.0004) and overall RVO (p=0.0243).
- Tarcocimab dosed 4 times vs aflibercept 6 times in first 24 weeks, showing extended durability.
- Safety favorable: low intraocular inflammation (1.4% vs 0.4%); no vasculitis or retinal artery occlusion.
- Full primary results to be presented at ophthalmology congresses in September 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017022015232/0000950170-22-015232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017022015232/kod-20220808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-015232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer